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SUMMARY Both bacterial vaginosis and candidiasis are commonly 
seen in pregnancy, with marked differences in pregnancy outcome. 
The aim of this study was to assess the effect of antifungal treatment 
on the prevalence of bacterial vaginosis in early pregnancy. This 
prospective randomized study included 126 women in early 
pregnancy with heavy vaginal yeast colonization and 88 healthy 
controls. Vaginal flora was evaluated on initial visit and on two 
check-ups for the presence of bacterial vaginosis. Half of the heavily 
colonized patients received an antimycotic agent (clotrimazole). The 
prevalence of vaginosis was compared among the three groups. χ2-
test and Fisher’s exact test were used for statistical analysis. Three 
of 72 (4.2%) yeast-free controls, two of 79 (2.5%) yeast infected but 
not treated patients, and nine of 63 (14.3%) infected and treated 
patients presented with bacterial vaginosis 4 weeks after the initial 
visit. There was a statistically significant increase in the prevalence 
of bacterial vaginosis (p<0.03) in yeast infected and treated patients 
as compared to colonized and untreated patients. Treatment of 
candidiasis in early pregnancy may contribute to an increased rate 
of bacterial vaginosis.
KEY WORDS: bacterial vaginosis, candidiasis, therapy
INTRODUCTION
 There is a continuous world-wide dilemma 
about the influence of sexually transmitted patho-
gens and vaginal commensals on the outcome of 
pregnancy. The majority of controversies have fo-
cused on the pathogens of endogenous origin, for 
instance bacterial vaginosis (BV), candidiasis and 
group B streptococcus, since those strictly related 
to sexual transmission (chlamydia, gonococci, 
viruses) have been documented to elicit a more 
clear effect on pregnancy outcome. A changing 
pattern of screening strategies is recommended 
in different countries evenly characterized by simi-
lar prevalence of particular pathogens and similar 
medical standards (1-4). For example, there is ba-
sic disagreement between the Centers for Disease 
Control and Prevention 2002 recommendations 
(1) for BV screening, and results of a recent meta-
analysis of BV as a risk factor for preterm delivery 
published by authors from University of Vienna (5). 
With a huge impact of BV on the complication rate 
in early pregnancy, especially spontaneous abor-
tions and preterm labor (odds ratio up to 7.55), 
is it reasonable to limit appropriate screening 
tests? 
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Such confusion also applies to the understanding 
of yeast vaginal colonization, distinguishing be-
tween commensalism and infection, the need and 
effectiveness of treatment. The expected result of 
treating candidal infection is the renewal of normal 
vaginal flora, which ultimately leads to better preg-
nancy outcome by lowering the rate of ascending 
transmission, and decreasing chorioamniotic in-
fections, thus improving the well-being of the baby 
after delivery. Generally, the negative influence of 
vaginal yeast colonization on pregnancy outcome 
is very doubtful. The question is whether antifungal 
therapy in early pregnancy has a positive or nega-
tive effect on the structure of vaginal flora. Such 
treatment could lead to the selection of potentially 
hazardous bacterial populations for pregnancy. 
We performed a prospective randomized study to 
assess the effect of vaginal yeast infection treat-
ment on the incidence of BV in early pregnancy.
PATIENTS AND METHODS
 The study included a population of 126 preg-
nant women aged 19-35, diagnosed with candidal 
vaginal infection, and 88 healthy pregnant controls 
aged 18-33 with vaginal flora estimated as normal. 
These pregnant patients were examined on initial 
check-up at University Department of Gynecol-
ogy, Poznan University Medical School. The vagi-
nal ecosystem was estimated after taking vaginal 
samples for microbiologic cultures and Gram stain 
testing. The inclusion criteria were 5 to 8 weeks 
of gestation, the lack of endocervical inflamma-
tory reaction confirmed by microscopic examina-
tion of endocervical exudate, which showed all 
patients to have less than 10 polymorphonuclear 
leukocytes on HPF microscopy, and absence of 
any clinical signs of cervical inflammation (muco-
purulent exudate, bleeding, edema). Patients with 
BV were excluded from the study. Women who ex-
hibited redness of the exocervix and no other cer-
vical inflammatory features were eligible to enter 
the study. According to mycologic (yeast coloniza-
tion) and clinical status patients were classified as 
shown in Table 1.
 A patient was described as free from yeast 
if presenting no subjective or objective clinical 
symptoms (speculum examination), along with 
negative microscopic tests and culture (n=72). 
If no clinical symptoms were present but a small 
number of yeast cells were seen on microscopy 
and/or a slight growth on Sabouraud medium was 
observed, the patient was considered healthy 
and described as “light to moderate colonization” 
(n=16). Pregnant women who were heavily colo-
nized were characterized by vaginal exudate with-
out itching or burning, while some only noticed a 
slight discharge. Microscopy revealed inflamma-
tory vaginal exudate, presence of pseudohyphae 
and intense growth in culture (n=36). The symp-
tomatic group (n=40) presented with all typical 
clinical symptoms and microbiologic features of 
inflammatory exudate. Every other patient with 
yeast inflammation (n=126) randomly received a 
standard 7-day vaginal treatment with antifungal 
agent (clotrimazole 2x100 mg) introduced within 3 
days from initial examination.
 In all groups, microbiologic and clinical studies 
were repeated 2 and 4 weeks after the first check-
up, i.e. between the 9th and 12th week of gestation, 
using the same methods. All procedures were per-
formed in accordance with ethical standards of the 
Committee on Human Experimentation.
Statistical analysis was made with the use of χ2-
test and Fisher’s exact test.
RESULTS
 Three of 72 yeast-free controls (4.2%), two of 
79 (2.5%) yeast infected but not treated patients, 
and nine of 63 (14.3%) infected and treated pa-
tients presented with BV 4 weeks after the initial 
visit (Table 2). 
 The prevalence of BV in the control group was 
relatively low as compared to what is seen in ado-
Table1. Pregnant patients yeast colonization status
                       No yeast       Light to moderate         Heavy colonization      Heavy colonization
                                                Colonization                 No symptoms               Symptomatic 
Controls 72                  16
(n=88)            
Candidal  -                -                     76 50
infection
(n=126)                                                         
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lescents, while the prevalence recorded in the 
treated group corresponded to the rates often re-
ported in Europe (6). There was no statistical sig-
nificance in the prevalence of vaginosis in healthy 
controls and yeast infected untreated controls 
(p=0.669) at the end of the study. Yet, the number 
of BV positive pregnant women previously treated 
with antifungal agent increased during the second 
and at the last check-up. As a result, there was a 
statistically significant difference in BV prevalence 
(p<0.03) as compared with the yeast infected but 
untreated pregnant women. In addition, in all pa-
tients the onset of vaginosis after therapy started 
no sooner than two weeks of the treatment.
DISCUSSION
 There is still some uncertainty in understanding 
the presence of Candida sp. in the female genital 
tract, but it is generally believed that, likewise the 
skin and gastrointestinal tract, yeast is an oppor-
tunistic, normal flora if limited in number and viru-
lence. Candidiasis is detectable in vaginal flora of 
approximately 20% of the female population in Po-
land (7), with an increasing (iatrogenic?) tendency 
observed during the past twenty years. In preg-
nant women, an increased rate of yeast coloniza-
tion is commonly observed. The symptoms are 
milder but there is a high recurrence rate of infec-
tion after treatment. Nature rarely works against 
the well-being of an organism it should protect, 
so why should it promote vaginal yeast growth if 
it were in fact harmful to pregnancy? The prac-
tical answer is known from a prospective Ameri-
can study (8): moderate and even heavy Candida 
vaginal colonization is not risky for pregnancy and 
the newborn. It is important to note, however, that 
some species other than Candida albicans may 
cause higher morbidity, most often during second 
trimester. Oral thrush in newborns is more often 
seen with a Candida infected mother. Fungi are 
occasionally isolated from amniotic fluid and are of 
medical concern in the presence of a foreign body 
such as cervical suture. 
 From the microbiologic point of view, normal 
vaginal flora and that contaminated by Candida 
sp. (with or without inflammation) is still free from 
domination by potentially more hazardous micro-
organisms, mainly anaerobic bacteria. In other 
words, if a woman has a yeast infection she can-
not suffer from BV at the same time. As the results 
of the study show, eliminating yeast from vagina 
of pregnant women later increases the rate of BV. 
This phenomenon is difficult to explain, because 
clotrimazole, like many similar antifungal agents, 
is characterized by in vitro antibacterial activity 
against many bacterial species involved in the ori-
Table 2. Microbiologic status, antifungal treatment results and prevalence of bacterial vaginosis (BV) at 
2 and 4 weeks of treatment
                                     2 weeks of initial visit                                     4 weeks of initial visit
Status on                  yeast         yeast          BV          BV                yeast        yeast         BV         BV
initial visit            negative     positive   negative   positive          negative   positive   negative  positive
Controls with
no yeast (72)*        72              0              70              2                    64             8              69            3
Controls light/
moderate col. (16)* 1                15            16             0                     2             14             15            1
Heavy colon, no
symptoms (38)*      1               37             37              1                    2             36            37            1
Heavy colon +
symptoms (25)*      0               25              25             0                    1             24            25            0
Heavy colon,no
symptoms (38)        32              6               38             0                   26            12            33            5
Heavy colon +
symptoms (25)       21               4               25             0                     7             18           21            4
*no antifungal treatment
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gin of BV. In fact, MIC90 ranges from <0.03 mg/L 
for Mobiluncus spp., 0.125 mg/L for Gardnerella 
vaginalis, 8 mg/L for Bacteroides fragilis group to 
>16 mg/L for Bacteroides urealyticus (9). In many 
conditions, the achieved therapeutic level may 
not be sufficient for eradication of anaerobic spe-
cies, especially those growing in the deeper lay-
ers of vaginal epithelium, where penetration of 
clotrimazole is poor as compared to, for example, 
fenticonazole (9). The other explanation is that 
clotrimazole (and many other medicines, mainly 
antibiotics) interferes with the delicate microbio-
logic balance in the vaginal exudate and promotes 
disturbances in antibiosis between several spe-
cies of bacteria and antibacterial yeast activity. 
This antifungal may also leave too much space for 
the growth of selected populations of vaginal flora 
by eliminating several aerobic species including 
coryneforms and streptococci, and by a variable 
effect on Lactobacillus sp. 
 A study of the potential influence of candidiasis 
treatment and the incidence of BV with the use of 
other antifungal agents is obviously needed.
 Since recent multi-center analyses have proved 
that vaginosis is related to abortion and other early 
pregnancy complications, they have prevented us 
from continuing the study to check pregnancy out-
come in women with untreated BV.
CONCLUSION
 The treatment of candidiasis in early pregnancy 
may contribute to an increased rate of BV. In or-
der to avoid such a risk, a delayed routine screen-
ing test for BV should be implemented after such 
therapy.
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